|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| - EUR | -.--% |
|
-1.95% | -8.87% |
| 10/11/23 | Alvotech, Stada Get EU Panel Backing for Stelara Biosimilar | MT |
| 25/07/23 | Xbrane Biopharma and Stada consider options for ranibizumab | FW |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 61 | 31/08/2018 | |
Boris Döbler
DFI | Director of Finance/CFO | - | 31/12/2022 |
Miguel Fernandez
CTO | Chief Tech/Sci/R&D Officer | 61 | 31/12/2014 |
| Director | Title | Age | Since |
|---|---|---|---|
Jens Steegers
BRD | Director/Board Member | 46 | 03/06/2014 |
Eric Cornut
BRD | Director/Board Member | 69 | 25/08/2016 |
Günter von Au
CHM | Chairman | 75 | 26/09/2017 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -.--% | -1.95% | - | - | 5.73B | ||
| +0.42% | +2.03% | +13.86% | +83.48% | 48B | ||
| +3.36% | +7.21% | +72.47% | +121.55% | 36.89B | ||
| +0.97% | +1.25% | -2.53% | +44.17% | 12.37B | ||
| +0.64% | +2.37% | +14.93% | +95.19% | 11.95B | ||
| +0.97% | +0.58% | +32.90% | +119.07% | 9.01B | ||
| +0.90% | +1.91% | +22.51% | +47.75% | 7.2B | ||
| +1.22% | +2.99% | +54.53% | -6.03% | 7.05B | ||
| -0.62% | +32.11% | -16.02% | +21.06% | 6.58B | ||
| +2.71% | +3.86% | +22.08% | +239.83% | 6.55B | ||
| Average | +0.96% | +3.93% | +23.86% | +85.12% | 15.13B | |
| Weighted average by Cap. | +1.29% | +3.29% | +30.00% | +91.06% |
Employees
-
Sector
Pharmaceuticals
- Stock Market
- Stocks
- SAZ Stock
Select your edition
All financial news and data tailored to specific country editions
















